There is no established strategy of how and when to treat coronary artery disease (CAD) in patients referred for transcatheter aortic valve implantation (TAVI). Simultaneous, single-stage treatment of both pathologies is a possible solution. We report our initial results of simultaneously performed transapical TAVI and elective percutaneous coronary interventions (PCI) in high-risk patients with severe aortic valve stenosis. Between April 2008 and July 2011, a total of 419 patients underwent transapical TAVI. Combined elective PCI and TAVI were performed in 46 (11%) patients. Only the most significant coronary lesion or lesions were treated. Technical success of the combined approach was 100%. The mean count of implanted stents per patient was 1.6 ± 1.0 (range, 1-5 stents). The 30-day mortality rates in the PCI and TAVI group was 4.3%. Survival at 12, 24 and 36 months of the PCI and TAVI group 87.1 ± 5.5, 69.7 ± 10.3 and 69.7 ± 10.3%, respectively. The results showed that the single-stage approach with combined elective PCI and TAVI is feasible and safe. It has become our primary choice for treatment of high-risk patients with severe aortic valve stenosis and CAD.
INTRODUCTION
Coronary artery disease (CAD) is found in 60-70% of patients referred for transcatheter aortic valve implantation (TAVI) [1] [2] [3] . There is no clear policy on how to treat concomitant CAD in these patients. It might be that only medical treatment of CAD is enough when TAVI eliminates severe aortic valve stenosis in elderly patients [4] . Another option is to treat CAD by percutaneous coronary intervention (PCI). This can be performed before or after TAVI, in a double-stage procedure. The possible alternative is to treat both pathologies simultaneously. Data about a single-stage, combined approach in a larger cohort of patients are still missing, and only anecdotal institutional reports are present [5] [6] [7] .
We report our initial institutional experience with single-stage approach (combined PCI and TAVI) for treatment of severe aortic valve stenosis and CAD in very high-risk patients.
PATIENTS AND METHODS

Patients
Between April 2008 and July 2011, transapical TAVI was performed in 419 patients with severe aortic valve stenosis. Forty six (11%) patients underwent combined, single-staged PCI and TAVI. The results of the preoperatively planned single-staged procedure (TAVI and PCI of the stenosed native coronary artery) were evaluated. PCI performed because of iatrogenic coronary artery obstruction during TAVI was not considered in this report. Written informed consent was obtained from all patients or their representatives. The study was approved by our institutional review board.
Transcatheter aortic valve implantation team, operative settings and specific technical considerations
Our TAVI team consisted of five cardiac surgeons, two cardiologists and two anaesthesiologists with expertise in echocardiography. A perfusionist and a heart-lung machine were present in the hybrid operating room. Transapical TAVI was performed through a left anterior mini-thoracotomy using balloon-expandable transcatheter stent-prosthetic xenograft valves of 23, 26 or 29 mm diameters with their delivering systems (both valves and the valve delivering systems; Edwards SAPIEN THV, Edwards Lifesciences, Irvine, CA, USA). It was performed under rapid ventricular pacing (160-180 beats/min) during balloon valvuloplasty and valve deployment as it has been originally described [8] with some modifications [9] . The procedure was monitored by fluoroscopy, angiography and continuous intra-operative transoesophageal echocardiography (TEE). TAVI was always done first, before PCI. PCI was principally performed via trans-femoral access. Standard catheters, guide-wires and stents of different manufacturers were used as for standard PCI at our institution. The contrast agent iopromide (ULTRAVIST ® -370, Bayer AG, Leverkusen, Germany) was used for angiography. All procedures were performed under general anaesthesia in our hybrid operating room with a monoplane angiography system (Siemens Artis zee, Siemens AG, Munich, Germany).
Principles for elective percutaneous coronary intervention during transcatheter aortic valve implantation
The primary aim in performing simultaneous PCI and TAVI was to prevent postoperative myocardial infarction without increasing the risks of the procedure. Only the most relevant coronary lesion(s) was/were treated. Coronary artery stenosis was regarded as significant only if the diseased artery vascularized a large myocardial territory and the stenosis put a large myocardial area at risk. It included (A) the left main coronary artery stenosis (LM) if was of more than 50% or (B) coronary stenosis of 90% or more found in (1) the proximal or mid left anterior descending (LAD), or (2) proximal or mid right coronary artery (if dominant artery), or (3) proximal or mid left circumflex artery stenosis (if dominant). The coronary lesion should be technically amenable to straightforward PCI. PCI should be able to be performed with a very high probability of success. Exceptionally, a complex PCI combined with TAVI was accepted only in patients who were thought not suitable for conventional surgery.
Intra-procedural anticoagulant medications
Immediately before the procedure, each patient received an intravenous bolus of heparin according to body weight (100 IU per kilogram). During the procedure, the activated coagulation time (ACT) was measured at intervals to achieve and maintain a steady level of heparin anticoagulation (ACT > 250 s, according to the valve manufacturer's recommendations). If cardiopulmonary bypass (CPB) was used, the initial dose of heparin was 300 IU/kg of body weight, and later on according to the ACT. At the end of the procedure, if there was no bleeding tendency, heparin was generally not neutralized with protamine.
Post-procedural anticoagulant and antiplatelet medications
Patients continuously received intravenous heparin until good mobilization of the patient was reached. The dose was maintained according to the partial thromboplastin time. All patients received standard dual antiplatelet therapy (aspirin, 100 mg daily; clopidogrel, 75 mg daily). Patients who underwent combined PCI and TAVI received an additional loading dose of 300 mg of clopidogrel. The therapy was given for at least 6 months.
Data collection and statistical analysis
All data concerning patients' comorbidities, morbidity, electrocardiogram (ECG) findings, laboratory data, operative and postoperative parameters, and early and late mortality were prospectively collected in an electronic database. The information about deaths of German patients was additionally obtained from the official state administrative office. Qualitative data are presented as number (n) and per cent. For quantitative data mean ± standard deviation (SD) were calculated. Analysis of survival was calculated according to Kaplan-Meier estimation. SPSS for Windows version 18.01 was used for statistical analysis. A P-value of < 0.05 was considered statistically significant.
RESULTS
The preoperatively planned combined PCI and TAVI procedure was performed on an elective basis in 43 patients. These 43 patients presented 10.3% of all 419 our patients who underwent TAVI. Additionally, in 3 patients with CAD and aortic valve stenosis who were in cardiogenic shock, the preoperatively planned combined procedure (PCI and TAVI) was performed as an emergency or rescue combined procedure. They presented 0.7% of all our patients who underwent TAVI. The baseline demographic factors, risk factors, haemodynamic measurements and laboratory values are given in Table 1 . The early outcome, rate of complications and follow-up survival in patients who underwent TAVI at our institution have recently been reported (reports on up to 358 patients) [10] [11] [12] [13] [14] .
Intra-procedural course of combined percutaneous coronary intervention and transcatheter aortic valve implantation procedure
Technical procedural success was achieved in all patients (Table 2 ). There was no conversion to open heart surgery. Trans-femoral approach was used for PCI in all patients. Additional standard cardiac surgery was performed in two (4%) patients (apical left ventricular aneurysmectomy in one, off-pump anastomosis of the left internal thoracic artery to LAD in one). One patient additionally received stenting of the left common iliac artery due to symptomatic occlusive peripheral arterial disease. There was no aortic dissection, no disruption of the aortic annulus and no valve dislocation. Unplanned PCI of the LM was performed in one patient because of intra-procedural narrowing of the LM by a huge amount of leaflet calcification during valve deployment. In one patient, there was valve dysfunction immediately after valve implantation: the patient developed pulmonary oedema due to severe transvalvular regurgitation. She was put on CPB, and an additional transcatheter valve of the same type and size was placed in the already implanted valve, and PCI was performed as planned. Additional intra-aortic ballloon pump (IABP) was placed prophylactically, and the patient was weaned from CPB. However, she received extracorporeal membrane oxygenation (ECMO) for 24 h for lung support. In the further course she initially recovered but developed pulmonary problems with sepsis and multiorgan failure and died.
Elective femoro-femoral CPB was applied in 4 (8.7%) patients with severe cardiogenic shock and/or poor LVEF (LVEF 10-20%). The mean CPB time was 85 min with a range from 7 to 168 min. There was one (2%) use of CPB on an emergency basis (as described above).
Target vessels
Of the 46 patients who underwent combined PCI and TAVI (group III), a total of 16 (34.8%) had single-vessel CAD, 15 (32.6%) double-vessel disease and 15 (32.6%) triple-vessel disease. A critical coronary stenosis amenable to a technically simple PCI approach was treated in most of the patients (38 of 46 patients; 82.6%) (Fig. 1, Table 3) . A minority of patients (8 of 46 patients; 17.4%) had a complex PCI involving either the LM (one of eight patients), or two coronary arteries (five of eight patients), or one coronary artery (two of eight patients) (Figs. 2  and 3 , Table 3 ). The mean count of implanted stents per patient was 1.6 ± 1.0 with a range from 1 to 5 stents (Table 4) .
Post-procedural course after combined percutaneous coronary intervention and transcatheter aortic valve implantation procedure
There was one postoperative re-thoracotomy because of a huge haematoma in the left pleural space. At revision, there was no identifiable active bleeding. The patient developed multi-organ failure and died. One patient had new onset of ECG changes on the fourth postoperative day after an uneventful combined procedure. She was treated with immediate re-PCI because of stent thrombosis (erroneously, clopidogrel was not taken) and had an uneventful further postoperative course. There were no other postoperative ECG signs of myocardial infarction or a new neurological event. One patient (2%) required pacemaker implantation because of a higher-grade AV block postoperatively. There was one patient with late postoperative wound problems and one with prosthetic endocarditis that was treated only conservatively.
Early mortality
Early mortality in patients with CAD who had combined PCI and TAVI was 4.3% (2 of 46 patients died, as described above). 
Follow-up survival
Survival at 1, 2 and 3 years was 87.1 ± [standard error] 5.5, 69.7 ± 10.3 and 69.7 ± 10.3%, respectively (Fig. 4) .
DISCUSSION
Our initial results with simultaneous PCI and TAVI showed feasibility of the combined, single-stage procedure. It demonstrated no increase of the procedural complexity of TAVI when PCI was additionally performed. The combined procedure was performed as planned in all scheduled patients. The primary aim in performing simultaneous PCI and TAVI was to prevent postoperative myocardial infarction without increasing the risk of the procedure. We accepted this combined, single-staged strategy very early after introduction of the TAVI Unplanned PCI (performed because of intra-procedural narrowing of the LM by huge amount of leaflet calcification during valve deployment). programme at our institution in April 2008 [10] . Our decision to use this approach was forced after one of our first patients experienced acute myocardial infarction after TAVI and was thereafter treated with PCI. Therefore, we decided to treat only the most relevant coronary lesion(s) by PCI simultaneously with TAVI. This is an old surgical principle [15] applied in the contemporary treatment of elderly high-risk patients with aortic valve stenosis and CAD: more than 20 years ago, at the beginning of the surgical era of comprehensive treatment of octogenarians with severe aortic valve stenosis, additional coronary artery bypass grafting (CABG) was performed only on the relevant coronary artery lesion(s), in order to keep the aortic cross-clamp time (reducing myocardial ischaemia) and the operative time as short as possible. The results were very good without any consequence of non-treatment of all coronary artery lesions [15] . However, we accepted a complex PCI in eight patients because of their critical preoperative state or a very high risk for conventional surgery.
Possible advantages of the single-stage procedure
The theoretical advantage of this combined, single-staged strategy is the complete elimination of the possible complications from a pathology remaining untreated during the waiting time for the second procedure. The combined, single-stage procedure treats all pathologies during the same time without the need for further interventions. It may reduce the incidence of post-procedural myocardial infarction and eliminates the risk of the second pathology remaining untreated. If PCI is performed first, the patients remain at risk for decompensation while aortic valve stenosis is left untreated. Otherwise, if TAVI is performed first, the risk of myocardial infarction may be elevated as a consequence of untreated CAD. Furthermore, a potential benefit of additional PCI would be an improvement in the New York Heart Association class or in the quality of life. Also, the approach can reduce operational costs.
Possible drawbacks of the single-stage strategy
Early stent thrombosis with acute myocardial infarction may happen, as is seen in 1-3% of patients after PCI. Although dual antiplatelet therapy with clopidogrel and aspirin is obligatory for TAVI patients, this risk remains, and myocardial infarction occurred in one of our patients. Therefore, the goal of the combined, single-stage procedure to reduce the risk of postprocedural myocardial infarction might be its own drawback. The timing and dosage of clopidogrel in isolated TAVI remains controversial. In combined procedures clopidogrel preloading may reduce the risk of stent thrombosis as in elective PCI. Post-implant renal failure related to the additional amount of contrast medium necessary for PCI is a possible complication. However, in the present cohort, we did not identify such serious problems.
Aortic stenosis is 'the most proximal coronary artery stenosis'
Patients with CAD have a risk of possible myocardial ischaemia during the various phases of TAVI including rapid ventricular pacing. It seems logical that PCI should be performed first.
However, severe aortic stenosis should be considered as 'the most proximal coronary artery stenosis' because it reduces both systemic and myocardial perfusion. TAVI eliminates aortic stenosis and, therefore, per se improves myocardial perfusion even when a concomitant coronary artery stenosis is present. Importantly, we observed myocardial ischaemia-if it occurs during TAVI-to be rather a consequence of debris microembolization during balloon valvuloplasty than a consequence of concomitant CAD. During the combined procedure (TAVI and PCI) either TAVI or PCI can be performed first. Independently of whichever procedure is performed first, there are two types of possible complications: (1) complications resulting from the procedure performed first (iatrogenic i.e. coronary dissection if PCI is performed first) and (2) complications resulting from the untreated pathology (i. e. acute onset of heart failure during PCI in a patient with severe aortic stenosis when the PCI is performed first). It is our intention to perform the main procedure first (TAVI) without complications and, if complications occur, to be able to treat them. This is our main reason for performing TAVI first and then PCI.
Limitations of the study
The main limitations of this observational study are the small number of patients. The patients were not randomized; there was no control group of patients with significant CAD who fulfilled the criteria for simultaneous PCI but were not treated with simultaneous PCI.
CONCLUSIONS
Simultaneous treatment of the most significant coronary artery lesion or lesions with PCI during TAVI is safe and feasible. It has become our primary choice for treatment of high-risk patients with severe aortic valve stenosis and significant CAD. The primary aim in performing a simultaneous procedure is to prevent postoperative myocardial infarction without increasing the risks of the procedure. 
